ClinicalTrials.gg
Active, not recruitingNCT07082426EASEUpdated Apr 8, 2026

Early System Experience With the Abbott Balloon-expandable TAVI System: First-In-Human Study

An interventional study of Balloon expandable TAVI in Symptomatic Severe Aortic Stenosis, sponsored by Abbott Medical Devices. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2024, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Aortic Valve Stenosis by Abbott — 4 open to participants now, 9 under way, none of them phase 3. Aortic Valve Stenosis · Abbott.

Enrollment
18th of 20
8 · median 177
Started
2024
with 1 other
No phase
19 of 26
2 open now
Registered
23rd of 26
by date

Among the 26 studies in Aortic Valve Stenosis by Abbott, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 with no phase, and was the 23rd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

4 of the 26 studies in Aortic Valve Stenosis by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Aortic Valve Stenosis by Abbott, or all of them as a file.
02

Study summary

Early System Experience with the Abbott Balloon-expandable TAVI System

Read the detailed description

The Early System Experience with the Abbott's balloon-expandable TAVI System first-in-human study ('EASE study') will evaluate preliminary clinical evidence on the safety and feasibility of the Abbott's balloon-expandable TAVI system for the treatment of patients with symptomatic severe aortic valve stenosis.

03

Conditions studied

  • Symptomatic Severe Aortic Stenosis

Keywords

  • Balloon Expandable TAVI
  • Transcatheter aortic valve implantation (TAVI)
  • Treatment of patients with symptomatic severe aortic valve stenosis
  • Aortic stenosis
  • Cardiovascular disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Increased surgical risk
  • Appropriate anatomy
  • At least 18 years of age
  • Willing to return for follow-up assessments

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing subjects
  • Anatomic or comorbid conditions
  • Evidence of acute myocardial infarction
  • Inoperable/ineligible for surgery
  • Renal disease requiring chronic dialysis
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Balloon expandable TAVI

    Device: Balloon expandable TAVI

Interventions

  • DeviceBalloon expandable TAVI

    Prospective, single-arm, multi-center early experience study.

06

What researchers measure

Primary outcomes

  1. Technical Success

    Successful access, delivery of the Abbott BE TAVI valve, and retrieval of the delivery system.

    Time frame: Post procedure

  2. Device success

    Intended performance of the valve

    Time frame: 30 days

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2027, 33 months after the start.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 33 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 24, 2025
StartActual
Nov 21, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Sep 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07082426
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Nov 21, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Ashish Oza
study director · Abbott Structural Heart

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion